EYPT vs OCUL
EYPT: EyePoint Pharmaceuticals is developing sustained-delivery, intraocular tyrosine kinase inhibitor therapeutics to treat leading retinal diseases like wet AMD and DME. OCUL: Ocular Therapeutix develops sustained-release, bioresorbable hydrogel-based ocular therapies to address chronic and acute eye diseases.
Side-by-side fundamentals
| Metric | EYPT | OCUL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.46 | $7.51 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $298M | $1.6B | |
| Net margin FY2025, SEC XBRL | -739.4% | -511.9% | OCUL higher |
| Operating margin FY2025, SEC XBRL | -776.0% | -519.8% | OCUL higher |
| ROE FY2025, SEC XBRL | -75.8% | -40.6% | OCUL higher |
| ROA FY2025, SEC XBRL | -63.7% | -32.9% | OCUL higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.14 | EYPT lower |
| Revenue growth (YoY) as of 2026-09-03 | -94.6% | -8.1% | OCUL higher |
| Revenue CAGR (3y) SEC XBRL | -8.8% | +0.3% | OCUL higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.29 | 1.35 | |
| 1-year return as of 2026-10-08 close | -75.1% | -36.9% | OCUL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.